Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Entegris enters its October 29 earnings report riding a 20% rally, fresh analyst coverage, and short sellers who have been quietly rebuilding positions into the move.
The most immediately newsworthy development is on the Street. Stifel initiated coverage this morning with a Buy rating and a $200 target, joining a consensus that has been almost uniformly positive since the Q2 print in August. Deutsche Bank upgraded to Buy in mid-August, lifting its target from $152 to $200 at the same time. UBS maintained Buy and raised to $215. Oppenheimer upgraded to Outperform. The mean target across the analyst community now sits at $175.58, roughly 6% above the current price of $166.32. Most of the analyst momentum has been one-directional: upward revisions and upgrades, with no recent downgrades in the data. The 12-month forward EPS estimate trajectory is particularly striking, scoring in the 98th percentile of the universe on year-on-year increase, which is the single strongest factor reading on the stock.
Short positioning tells a more nuanced story. At 5.4% of the free float, short interest is not extreme but is not trivial either. More interesting is the direction: shorts increased by roughly 12% over the past month, adding around 800,000 shares net into the rally. Over the past week that momentum reversed slightly, with short interest falling around 2%. The borrow market offers no particular read on conviction, cost to borrow is around 0.50%, essentially nothing, and availability is exceptionally loose at around 817% of short interest, meaning there are more than eight times as many shares available to borrow as are currently borrowed. Shorts are not under any squeeze pressure and could add further with ease. The put/call ratio at 0.62 is nearly in line with its 20-day average of 0.62, with a z-score of just 0.11, meaning options positioning is neutral: no unusual hedging demand ahead of the print.
The bull case rests on Entegris's positioning in advanced semiconductor materials, particularly its exposure to leading-edge fab buildouts where chipmakers expanding AI-related production require its purification solutions and specialty chemicals. The Q2 print delivered margin expansion and a guidance raise, and the stock responded with a 16% single-day gain. The company scores in the 99th percentile on dividend scoring, though the dividend history in the data is stale, last paid in mid-2022, so that ranking likely reflects something else in the scoring model rather than a current yield story. The bear case is more mechanical: gross margins may stall as fixed-cost absorption offsets volume gains, and with a PE near 35x and EV/EBITDA at 24.5x, the valuation has re-rated sharply alongside the stock, the PE multiple has expanded by nearly 5 points over the past 30 days alone.
Ownership is broadly institutional and growing. BlackRock holds 13.4% and added over a million shares in the latest reported period. T. Rowe Price holds 8.4% and added 835,000 shares. JP Morgan Asset Management is the most aggressive recent buyer among the top holders, adding 2.3 million shares to reach a 2.4% stake. Capital Research and State Street also added, though more modestly. All filings on the 13D/G register are passive Schedule 13G filings; there is no activist involvement. Insider activity since the Q2 print has been mostly mechanical: the CEO had shares withheld for taxes in August, the general counsel exercised options and sold the resulting shares, and a divisional president executed a similar option-exercise-and-sell under a pre-arranged 10b5-1 plan. There is no open-market buying by insiders to confirm management conviction at current prices.
ENTG has gained 8% this week, outperforming close peers sharply. FORM fell 6.4% over the same period, LRCX was flat, and ONTO dipped 1.1%. That divergence keeps the attention on the October 29 print: after the Q2 day-one move of 16% and a five-day follow-through of nearly 20%, the market has a clear template for what a beat-and-raise can do to this stock, and the question heading into November is whether a second consecutive upside print can be priced into a stock that has already rallied 70% in 2026.
See the live data behind this article on ORTEX.
Open ENTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
